| Year |
Citation |
Score |
| 2024 |
Gunenc D, Issa W, Gerald T, Zhou Q, Zhang S, Ibezue IC, Bhanvadia R, Tachibana I, Brugarolas J, Hammers H, Qin Q, Kapur P, Woldu S, Gaston K, Lotan Y, et al. Pathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy-Based Therapies and Undergoing Deferred Cytoreductive Nephrectomy (CN). Clinical Genitourinary Cancer. 102177. PMID 39218752 DOI: 10.1016/j.clgc.2024.102177 |
0.322 |
|
| 2024 |
Khaleel S, Ricketts C, Linehan WM, Ball M, Manley B, Turajilic S, Brugarolas J, Hakimi A. 2022 WUOF/SIU International Consultation on Urological Diseases: Genetics and Tumor Microenvironment of Renal Cell Carcinoma. Societe Internationale D'Urologie Journal : Siuj. 3: 386-396. PMID 38840811 DOI: 10.48083/BLPV3411 |
0.303 |
|
| 2024 |
Kapur P, Zhong H, Le D, Mukhopadhyay R, Miyata J, Carrillo D, Rakheja D, Rajaram S, Durinck S, Modrusan Z, Brugarolas J. Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma. Jci Insight. 9. PMID 38775158 DOI: 10.1172/jci.insight.176743 |
0.317 |
|
| 2024 |
Simoni M, Menegazzi C, Fracassi C, Biffi CC, Genova F, Tenace NP, Lucianò R, Raimondi A, Tacchetti C, Brugarolas J, Mazza D, Bernardi R. PML restrains p53 activity and cellular senescence in clear cell renal cell carcinoma. Embo Molecular Medicine. PMID 38730056 DOI: 10.1038/s44321-024-00077-3 |
0.373 |
|
| 2024 |
Brugarolas J, Obara G, Beckermann KE, Rini B, Lam ET, Hamilton J, Schluep T, Yi M, Wong S, Mao ZL, Gamelin E, Tannir NM. A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF10. PMID 38652038 DOI: 10.1158/1078-0432.CCR-23-3029 |
0.302 |
|
| 2024 |
Prakasam G, Mishra A, Christie A, Miyata J, Carrillo D, Tcheuyap VT, Ye H, Do QN, Wang Y, Reig Torras O, Butti R, Zhong H, Gagan J, Jones KB, Carroll TJ, ... ... Brugarolas J, et al. Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis. The Journal of Clinical Investigation. PMID 38386415 DOI: 10.1172/JCI170559 |
0.304 |
|
| 2023 |
Kapur P, Brugarolas J, Trpkov K. Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting. Cancers. 15. PMID 37627070 DOI: 10.3390/cancers15164043 |
0.344 |
|
| 2023 |
Bezwada D, Brugarolas J. Reporting on FH-deficient renal cell carcinoma using circulating succinylated metabolites. The Journal of Clinical Investigation. 133. PMID 37259915 DOI: 10.1172/JCI170195 |
0.318 |
|
| 2023 |
Rini BI, Brugarolas J, Atkins MB. Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma. Journal For Immunotherapy of Cancer. 11. PMID 36898737 DOI: 10.1136/jitc-2022-006361 |
0.3 |
|
| 2022 |
Kaushik AK, Tarangelo A, Boroughs LK, Ragavan M, Zhang Y, Wu CY, Li X, Ahumada K, Chiang JC, Tcheuyap VT, Saatchi F, Do QN, Yong C, Rosales T, Stevens C, ... ... Brugarolas J, et al. In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma. Science Advances. 8: eabp8293. PMID 36525494 DOI: 10.1126/sciadv.abp8293 |
0.313 |
|
| 2022 |
Kapur P, Zhong H, Araj E, Christie A, Cai Q, Kim D, Miyata J, Tcheuyap VT, Brandenburg O, Carrillo D, Pedrosa I, Brugarolas J, Cadeddu JA. Predicting Oncologic Outcomes in Small Renal Tumors. European Urology Oncology. PMID 36115820 DOI: 10.1016/j.euo.2022.08.003 |
0.313 |
|
| 2022 |
Kapur P, Rajaram S, Brugarolas J. The expanding role of BAP1 in clear cell renal cell carcinoma. Human Pathology. PMID 35932824 DOI: 10.1016/j.humpath.2022.07.022 |
0.358 |
|
| 2022 |
Yao C, Zhang T, Wu T, Brugarolas J. Facts and hopes for immunotherapy in renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35819272 DOI: 10.1158/1078-0432.CCR-21-2372 |
0.337 |
|
| 2022 |
Zhou J, Simon JM, Liao C, Zhang C, Hu L, Zurlo G, Liu X, Fan C, Hepperla A, Jia L, Tcheuyap VT, Zhong H, Elias R, Ye J, Henne WM, ... ... Brugarolas J, et al. An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma. Molecular Cell. PMID 35764091 DOI: 10.1016/j.molcel.2022.06.003 |
0.309 |
|
| 2022 |
Freifeld Y, Pedrosa I, Mclaughlin M, Correa RM, Louie AV, Maldonado JA, Tang C, Kadow B, Kutikov A, Uzzo RG, Porta C, Bucknell NW, Siva S, Brugarolas J, Margulis V, et al. Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. Urologic Oncology. PMID 35144866 DOI: 10.1016/j.urolonc.2021.12.018 |
0.309 |
|
| 2021 |
Hannan R, Christensen M, Hammers H, Christie A, Paulman B, Lin D, Garant A, Arafat W, Courtney K, Bowman I, Cole S, Sher D, Ahn C, Choy H, Timmerman R, ... Brugarolas J, et al. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. European Urology Oncology. PMID 34986993 DOI: 10.1016/j.euo.2021.12.001 |
0.309 |
|
| 2021 |
Reig Torras O, Mishra A, Christie A, McKenzie T, Onabolu O, Singla N, Plimack ER, Suárez C, Ornstein MC, Alpaugh RK, Elias R, Bowman IA, McKay RM, Przybycin C, Kapur P, ... Brugarolas J, et al. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. European Urology. PMID 34980496 DOI: 10.1016/j.eururo.2021.12.003 |
0.322 |
|
| 2021 |
Schoenhals JE, Mohamad O, Christie A, Zhang Y, Li D, Singla N, Bowman I, Arafat W, Hammers H, Courtney K, Cole S, Bagrodia A, Margulis V, Desai N, Garant A, ... ... Brugarolas J, et al. Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma. Advances in Radiation Oncology. 6: 100692. PMID 34646963 DOI: 10.1016/j.adro.2021.100692 |
0.304 |
|
| 2021 |
Kapur P, Gao M, Zhong H, Rakheja D, Cai Q, Pedrosa I, Margulis V, Xu L, Kinch L, Brugarolas J. Eosinophilic Vacuolated Tumor of the Kidney: A Review of Evolving Concepts in This Novel Subtype With Additional Insights From a Case With MTOR Mutation and Concomitant Chromosome 1 Loss. Advances in Anatomic Pathology. PMID 34009776 DOI: 10.1097/PAP.0000000000000299 |
0.307 |
|
| 2020 |
Kapur P, Christie A, Rajaram S, Brugarolas J. What morphology can teach us about renal cell carcinoma clonal evolution. Kidney Cancer Journal : Official Journal of the Kidney Cancer Association. 18: 68-76. PMID 34178206 |
0.313 |
|
| 2020 |
Reese B, Silwal A, Daugherity E, Daugherity M, Arabi M, Daly P, Paterson Y, Woolford L, Christie A, Elias R, Brugarolas J, Wang T, Karbowniczek M, Markiewski MM. Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma. Journal of Immunology (Baltimore, Md. : 1950). PMID 33158953 DOI: 10.4049/jimmunol.2000511 |
0.359 |
|
| 2020 |
Patel V, Elias R, Formella J, Schwartzman W, Christie A, Cai Q, Malladi V, Kapur P, Vazquez M, McKay R, Pedrosa I, Hannan R, Hammers H, Brugarolas J. Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. Journal For Immunotherapy of Cancer. 8. PMID 33139246 DOI: 10.1136/jitc-2020-001198 |
0.309 |
|
| 2020 |
Hwang JK, Agarwal N, Brugarolas J, Zhang T. Checking the Hippo in sarcomatoid renal cell carcinoma with immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33106290 DOI: 10.1158/1078-0432.CCR-20-3506 |
0.321 |
|
| 2020 |
Elias R, Zhang Q, Brugarolas J. The von Hippel-Lindau Tumor Suppressor Gene: Implications and Therapeutic Opportunities. Cancer Journal (Sudbury, Mass.). 26: 390-398. PMID 32947307 DOI: 10.1097/Ppo.0000000000000480 |
0.42 |
|
| 2020 |
Carbone M, Harbour JW, Brugarolas J, Bononi A, Pagano I, Dey A, Krausz T, Pass HI, Yang H, Gaudino G. Biological Mechanisms and Clinical Significance of Mutations in Human Cancer. Cancer Discovery. PMID 32690542 DOI: 10.1158/2159-8290.Cd-19-1220 |
0.404 |
|
| 2020 |
Dwivedi DK, Xi Y, Kapur P, Madhuranthakam AJ, Lewis MA, Udayakumar D, Rasmussen R, Yuan Q, Bagrodia A, Margulis V, Fulkerson M, Brugarolas J, Cadeddu JA, Pedrosa I. Magnetic Resonance Imaging Radiomics Analyses for Prediction of High-Grade Histology and Necrosis in Clear Cell Renal Cell Carcinoma: Preliminary Experience. Clinical Genitourinary Cancer. PMID 32669212 DOI: 10.1016/J.Clgc.2020.05.011 |
0.396 |
|
| 2020 |
Cai Q, Christie A, Rajaram S, Zhou Q, Araj E, Chintalapati S, Singla N, Cadeddu J, Margulis V, Pedrosa I, Rakheja D, McKay RM, Brugarolas J, Kapur P. Corrigendum to ''Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type'' [EBioMedicine 51 (2020) 102526]. Ebiomedicine. 55: 102707. PMID 32339934 DOI: 10.1016/J.Ebiom.2020.102707 |
0.416 |
|
| 2020 |
Singla N, Xie Z, Zhang Z, Gao M, Yousuf Q, Onabolu O, McKenzie T, Tcheuyap VT, Ma Y, Choi J, McKay R, Christie A, Torras OR, Bowman IA, Margulis V, ... ... Brugarolas J, et al. Pancreatic tropism of metastatic renal cell carcinoma. Jci Insight. 5. PMID 32271170 DOI: 10.1172/Jci.Insight.134564 |
0.464 |
|
| 2020 |
Bowman IA, Dakanali M, Mulgaonkar A, Hammers HJ, Sun X, Oz OK, Brugarolas J. An exploratory study of 89Zr-DFO-Atezolizumab ImmunoPET/CT in patients with locally advanced or metastatic renal cell carcinoma. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps759 |
0.418 |
|
| 2020 |
Patel VM, Elias R, Formella J, Schwartzman W, Christie A, Hammers HJ, Brugarolas J. Acute interstitial nephritis (AIN) following immune checkpoint inhibitor (ICI) therapy in metastatic RCC (mRCC) as a potential predictor of response. Journal of Clinical Oncology. 38: 674-674. DOI: 10.1200/Jco.2020.38.6_Suppl.674 |
0.305 |
|
| 2020 |
Elias R, Levonyak N, Christie A, Bowman IA, Kapur P, Hannan R, Hammers HJ, Brugarolas J. A real-world experience of immune checkpoint inhibitors (ICI) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 38: 647-647. DOI: 10.1200/Jco.2020.38.6_Suppl.647 |
0.356 |
|
| 2020 |
Schwartzman W, Elias R, Patel VM, Bowman AI, Chintalapati S, Kapur P, Hammers HJ, Brugarolas J. Safety and efficacy of immune checkpoint inhibitors (ICI) in metastatic non-clear cell renal cell carcinoma (nccRCC): An institutional experience. Journal of Clinical Oncology. 38: 640-640. DOI: 10.1200/Jco.2020.38.6_Suppl.640 |
0.453 |
|
| 2020 |
Elias R, Bowman IA, Hammers HJ, Brugarolas J. Immune checkpoint inhibitors (ICI) in clear cell renal cell carcinoma (ccRCC) following high-dose interleukin-2 (IL-2). Journal of Clinical Oncology. 38: 635-635. DOI: 10.1200/Jco.2020.38.6_Suppl.635 |
0.332 |
|
| 2020 |
Hammers HJ, Vonmerveldt D, Ahn C, Nadal RM, Drake CG, Folkert MR, Laine AM, Courtney KD, Brugarolas J, Song DY, Hannan R, Carducci MA. Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC). Journal of Clinical Oncology. 38: 614-614. DOI: 10.1200/Jco.2020.38.6_Suppl.614 |
0.388 |
|
| 2020 |
Freifeld Y, Israel H, Pedrosa I, Mcloughlin M, Correa R, Louie AV, Maldonado JA, Tang C, Kadow B, Kutikov A, Uzzo R, Porta C, Bucknell NW, Siva S, Brugarolas J, et al. Mp14-12 Stereotactic Ablative Radiation Therapy (Sabr) For Treatment Of Renal Cell Carcinoma (Rcc) With Inferior Vena Cava Tumor Thrombus (Ivc-Tt) The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000839.012 |
0.438 |
|
| 2020 |
All S, Diaz de Leon A, Mohamad O, Choy H, Hammers H, Sanjeevaiah A, Arafat W, Courtney K, Timmerman R, Brugarolas J, Hannan R. Prospective Safety and Feasibility trial of Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC) International Journal of Radiation Oncology*Biology*Physics. 108: e896-e897. DOI: 10.1016/j.ijrobp.2020.07.508 |
0.311 |
|
| 2019 |
Cai Q, Christie A, Rajaram S, Zhou Q, Araj E, Chintalapati S, Cadeddu J, Margulis V, Pedrosa I, Rakheja D, McKay RM, Brugarolas J, Kapur P. Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type. Ebiomedicine. PMID 31859241 DOI: 10.1016/J.Ebiom.2019.10.052 |
0.437 |
|
| 2019 |
Brugarolas J, Courtney KD, Ma Y, Diaz de Leon A, Christie A, Xie Z, Woolford L, Singla N, Joyce A, Hill H, Madhuranthakam AJ, Yuan Q, Xi Y, Zhang Y, Chang J, et al. HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor in Clear Cell Renal Cell Carcinoma Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31727677 DOI: 10.1158/1078-0432.Ccr-19-1459 |
0.425 |
|
| 2019 |
Singla N, Elias R, Ghandour RA, Freifeld Y, Bowman IA, Rapoport L, Enikeev M, Lohrey J, Woldu SL, Gahan JC, Bagrodia A, Brugarolas J, Hammers HJ, Margulis V. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. Urologic Oncology. PMID 31522865 DOI: 10.1016/J.Urolonc.2019.08.012 |
0.426 |
|
| 2019 |
Zhang Y, Schoenhals J, Christie A, Mohamad O, Wang C, Bowman I, Singla N, Hammers H, Courtney K, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Brugarolas J, et al. Stereotactic Ablative Radiotherapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 31377159 DOI: 10.1016/J.Ijrobp.2019.07.023 |
0.418 |
|
| 2019 |
Zhang Z, Luo D, Zhong X, Choi JH, Ma Y, Wang S, Mahrt E, Guo W, Stawiski EW, Modrusan Z, Seshagiri S, Kapur P, Hon GC, Brugarolas J, Wang T. SCINA: A Semi-Supervised Subtyping Algorithm of Single Cells and Bulk Samples. Genes. 10. PMID 31336988 DOI: 10.3390/Genes10070531 |
0.331 |
|
| 2019 |
Carlo MI, Hakimi AA, Stewart GD, Bratslavsky G, Brugarolas J, Chen YB, Linehan WM, Maher ER, Merino MJ, Offit K, Reuter VE, Shuch B, Coleman JA. Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. European Urology. PMID 31326218 DOI: 10.1016/J.Eururo.2019.06.015 |
0.352 |
|
| 2019 |
Diaz de Leon A, Pirasteh A, Costa DN, Kapur P, Hammers H, Brugarolas J, Pedrosa I. Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma. Radiographics : a Review Publication of the Radiological Society of North America, Inc. 180178. PMID 31199711 DOI: 10.1148/Rg.2019180178 |
0.431 |
|
| 2019 |
Vento J, Mulgaonkar A, Woolford L, Nham K, Christie A, Bagrodia A, de Leon AD, Hannan R, Bowman I, McKay RM, Kapur P, Hao G, Sun X, Brugarolas J. PD-L1 detection using Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response. Journal For Immunotherapy of Cancer. 7: 144. PMID 31155004 DOI: 10.1186/S40425-019-0607-Z |
0.302 |
|
| 2019 |
Yun EJ, Lin CJ, Dang A, Hernandez E, Guo J, Chen WM, Allison J, Kim N, Kapur P, Brugarolas J, Wu K, He D, Lai CH, Lin H, Saha D, et al. Down-regulation of human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31000589 DOI: 10.1158/1078-0432.Ccr-18-3004 |
0.363 |
|
| 2019 |
Levine RL, Brugarolas J, Abate-Shen C. Decision letter: Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition Elife. DOI: 10.7554/Elife.44161.050 |
0.365 |
|
| 2019 |
Diab A, Marcondes M, Kotzin B, Tagliaferri MA, Hoch U, Li Y, Cattaruzza F, Zalevsky J, Brohl AS, Brugarolas J, Bilen MA, Gupta S, Domingo Musibay E, Conley AP, Borazanci EH, et al. Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial). Journal of Clinical Oncology. 37: 26-26. DOI: 10.1200/Jco.2019.37.8_Suppl.26 |
0.325 |
|
| 2019 |
Udayakumar D, Dwivedi D, Zhang Z, Xi Y, Wang T, Madhuranthakam AJ, Kapur P, Fulkerson M, Leon ADd, Lewis M, Cadeddu JA, Margulis V, Brugarolas J, Bagrodia A, Pedrosa I. Assessment of intratumor heterogeneity using imaging texture features in clear cell renal cell carcinoma. Journal of Clinical Oncology. 37: 663-663. DOI: 10.1200/Jco.2019.37.7_Suppl.663 |
0.437 |
|
| 2019 |
Elias R, Yan F, Singla N, Levonyack N, Formella J, Christie A, Kapur P, Bowman AI, Hammers HJ, Hannan R, Brugarolas J. Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients. Journal of Clinical Oncology. 37: 645-645. DOI: 10.1200/Jco.2019.37.7_Suppl.645 |
0.406 |
|
| 2019 |
Cai Q, Christie A, Zhou Q, Araj E, Cadeddu JA, Margulis V, Singla N, Rajaram S, Pedrosa I, Rakheja D, McKay R, Brugarolas J, Kapur P. The role of architectural patterns and cytologic features in the prognosis of clear cell renal cell carcinoma. Journal of Clinical Oncology. 37: 632-632. DOI: 10.1200/Jco.2019.37.7_Suppl.632 |
0.365 |
|
| 2019 |
Singla N, Elias R, Ghandour R, Freifeld YN, Bowman AI, Woldu SL, Gahan J, Bagrodia A, Brugarolas J, Hammers HJ, Margulis V. Safety and feasibility of nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma. Journal of Clinical Oncology. 37: 619-619. DOI: 10.1200/Jco.2019.37.7_Suppl.619 |
0.438 |
|
| 2019 |
Zhang Y, Schoenhals J, Christie A, Wang C, Mohamad O, Singla N, Desai N, Choy H, Courtney KD, Bagrodia A, Margulis V, Bowman IA, Timmerman RD, Brugarolas J, Hannan R. Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer. Journal of Clinical Oncology. 37: 599-599. DOI: 10.1200/Jco.2019.37.7_Suppl.599 |
0.415 |
|
| 2019 |
Singla N, Onabolu O, Woolford L, Stevens C, Tcheuyap V, McKenzie T, Yousuf Q, Ma Y, Choi J, Zhang Z, Xie Z, Wang T, McKay R, Christie A, Pedrosa I, ... ... Brugarolas J, et al. Unraveling the molecular profile underpinning pancreatic tropisms in metastatic clear cell renal cell carcinoma. Journal of Clinical Oncology. 37: e16096-e16096. DOI: 10.1200/JCO.2019.37.15_SUPPL.E16096 |
0.328 |
|
| 2019 |
Udayakumar D, Zhang Z, Dwivedi D, Xi Y, Wang T, Kapur P, Yousuf Q, Joyce A, Hajibeiji A, Fulkerson M, Leon ADd, Lewis M, Madhuranthakam AJ, Cadeddu JA, Bagrodia A, ... ... Brugarolas J, et al. Dynamic contrast-enhanced MRI to predict intratumoral molecular heterogeneity in clear cell renal cell carcinoma. Journal of Clinical Oncology. 37: 4580-4580. DOI: 10.1200/Jco.2019.37.15_Suppl.4580 |
0.331 |
|
| 2019 |
Elias RM, Singla N, Bowman IA, Kapur P, Hannan R, Hammers H, Brugarolas J. Abstract 4106: Outcomes of combined ipilimumab and nivolumab therapy following progression on nivolumab monotherapy in renal cell carcinoma: A retrospective cohort study Cancer Research. 79: 4106-4106. DOI: 10.1158/1538-7445.Sabcs18-4106 |
0.391 |
|
| 2019 |
Singla N, Choi J, Onabolu O, Woolford L, Stevens C, Tcheuyap V, McKenzie T, Xie Z, Wang T, McKay R, Christie A, Kapur P, Rini B, Brugarolas J. Abstract 2505: Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma Cancer Research. 79: 2505-2505. DOI: 10.1158/1538-7445.Sabcs18-2505 |
0.419 |
|
| 2019 |
Udayakumar D, Zhang Z, Dwivedi D, Xi Y, Wang T, Madhuranthakam A, Kapur P, Hajibeigi A, Joyce A, Yousuf Q, Fulkerson M, Leon ADd, Lewis M, Cadeddu J, Bagrodia A, ... ... Brugarolas J, et al. Abstract 1397: Quantitative MR imaging measures predict intratumoral molecular heterogeneity in clear cell renal cell carcinoma Cancer Research. 79: 1397-1397. DOI: 10.1158/1538-7445.Am2019-1397 |
0.406 |
|
| 2019 |
Singla N, Elias R, Ghandour R, Freifeld Y, Bowman I, Woldu S, Gahan J, Bagrodia A, Brugarolas J, Hammers H, Margulis V. Pd03-09 Safety And Feasibility Of Nephrectomy After Receipt Of Immune Checkpoint Inhibitors For Renal Cell Carcinoma The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555045.12857.B2 |
0.425 |
|
| 2019 |
Singla N, Woolford L, Stevens C, Tcheuyap V, Onabolu O, Xie Z, McKay R, Wang T, Christie A, Gahan J, Bagrodia A, Raj G, Sagalowsky A, Lotan Y, Cadeddu J, ... ... Brugarolas J, et al. Mp21-06 Leveraging A Robust Patient-Derived Xenograft Platform To Characterize Predictors For Engraftment And Oncologic Outcomes In Renal Cell Carcinoma Patients The Journal of Urology. 18. DOI: 10.1016/S1569-9056(19)30062-4 |
0.44 |
|
| 2019 |
Pop LM, Manna S, Christley S, Freifeld Y, Vo DT, Filatenkov A, Kapur P, Monson N, Pedrosa I, Brugarolas J, Timmerman RD, Margulis V, Cowell LG, Hannan R. Immune Correlates of Abscopal Response in a Lead-in Phase II Trial of Neoadjuvant Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.430 |
0.408 |
|
| 2019 |
Schoenhals J, Mohamad O, Christie A, Garant A, Desai NB, Bowman I, Courtney K, Hammers H, Timmerman RD, Brugarolas J, Hannan R. Stereotactic Ablative Radiotherapy for Oligoprogressive Metastatic Renal Cell Carcinoma International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1957 |
0.438 |
|
| 2019 |
Li D, Christie A, Bowman I, Brugarolas J, Hannan R. Safety of Concurrent Hypofractionated Radiation Therapy and Systemic Therapy for Renal Cell Cancer International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1953 |
0.357 |
|
| 2019 |
Manna S, Mulgaonkar A, Woolford L, Nham K, Hao G, Pop LM, Bowman I, Brugarolas J, Sun X, Hannan R. Immuno-PET Evaluation of In Vivo Therapeutic Resistance in Renal Cell Carcinoma Patient-Derived Xenografts International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1064 |
0.397 |
|
| 2018 |
Wardak Z, Christie A, Bowman A, Stojadinovic S, Nedzi L, Barnett S, Patel T, Mickey B, Whitworth T, Hannan R, Brugarolas J, Timmerman R. Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma. Clinical Genitourinary Cancer. PMID 30595522 DOI: 10.1016/J.Clgc.2018.11.006 |
0.412 |
|
| 2018 |
Bowman IA, Bent A, Le T, Christie A, Wardak Z, Arriaga Y, Courtney K, Hammers H, Barnett S, Mickey B, Patel T, Whitworth T, Stojadinovic S, Hannan R, Nedzi L, ... ... Brugarolas J, et al. Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases. Clinical Genitourinary Cancer. PMID 30538068 DOI: 10.1016/J.Clgc.2018.11.007 |
0.373 |
|
| 2018 |
Graham J, Heng DYC, Brugarolas J, Vaishampayan U. Personalized Management of Advanced Kidney Cancer. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 330-341. PMID 30231375 DOI: 10.1200/EDBK_201215 |
0.302 |
|
| 2018 |
Woldu SL, Matulay JT, Clinton TN, Singla N, Freifeld Y, Sanli O, Krabbe LM, Hutchinson RC, Lotan Y, Hammers H, Hannan R, Brugarolas J, Bagrodia A, Margulis V. Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. Clinical Genitourinary Cancer. PMID 30217763 DOI: 10.1016/J.Clgc.2018.08.001 |
0.303 |
|
| 2018 |
Elias R, Kapur P, Pedrosa I, Brugarolas J. Renal-Cell Carcinoma Pseudoprogression With Clinical Deterioration: To Hospice and Back. Clinical Genitourinary Cancer. PMID 30100272 DOI: 10.1016/j.clgc.2018.07.015 |
0.303 |
|
| 2018 |
Wang T, Lu R, Kapur P, Jaiswal BS, Hannan R, Zhang Z, Pedrosa I, Luke JJ, Zhang H, Goldstein LD, Yousuf Q, Gu YF, McKenzie T, Joyce A, Kim MS, ... ... Brugarolas J, et al. An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. Cancer Discovery. PMID 29884728 DOI: 10.1158/2159-8290.Cd-17-1246 |
0.436 |
|
| 2018 |
Stukalin I, Wells JC, Fraccon A, Pasini F, Porta C, Lalani AA, Srinivas S, Bowman IA, Brugarolas J, Lee J, Donskov F, Beuselinck B, Bamias A, Rini BI, Sim H, et al. Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) Kidney Cancer. 2: 31-36. DOI: 10.3233/KCA-170020 |
0.306 |
|
| 2018 |
Xie W, DiNatale R, Hakimi AA, Donskov F, Porta C, Reaume MN, Basappa NS, Hansen AR, Rini BI, Beuselinck B, Bjarnason GA, Srinivas S, Brugarolas J, Rha SY, Wood L, et al. Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy. Journal of Clinical Oncology. 36: 667-667. DOI: 10.1200/Jco.2018.36.6_Suppl.667 |
0.424 |
|
| 2018 |
Bowman IA, Bent A, Le T, Christie A, Wardak Z, Mickey B, Timmerman RD, Hannan R, Brugarolas J. Improved survival rates in kidney cancer patients with brain metastases treated with modern multidisciplinary approaches. Journal of Clinical Oncology. 36: 601-601. DOI: 10.1200/Jco.2018.36.6_Suppl.601 |
0.32 |
|
| 2018 |
Woldu SL, Matulay JT, Clinton TN, Singla N, Freifeld YN, Sanli ON, Krabbe L, Hutchinson RC, Lotan Y, Hammers HJ, Hannan R, Brugarolas J, Bagrodia A, Margulis V. Utilization and survival implications of a delayed approach to targeted therapy for metastatic renal cell carcinoma: A nationwide cancer registry study. Journal of Clinical Oncology. 36: 586-586. DOI: 10.1200/Jco.2018.36.6_Suppl.586 |
0.393 |
|
| 2018 |
Woldu S, Matulay J, Clinton T, Singla N, Freifeld Y, Sanli O, Krabbe L, Hutchinson R, Lotan Y, Hammers H, Hannan R, Brugarolas J, Bagrodia A, Margulis V. Pd24-04 Incidence And Outcomes Of Delayed Targeted Therapy Following Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma: A Nationwide Cancer Registry Study The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1197 |
0.392 |
|
| 2017 |
Yip SM, Ruiz Morales JM, Donskov F, Fraccon A, Basso U, Rini BI, Lee JL, Bjarnason GA, Sim HW, Beuselinck B, Kanesvaran R, Brugarolas J, Koutsoukos K, Fu SYF, Yuasa T, et al. Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). Kidney Cancer. 1: 41-47. PMID 30334003 DOI: 10.3233/KCA-160002 |
0.403 |
|
| 2017 |
Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017742627. PMID 29257710 DOI: 10.1200/Jco.2017.74.2627 |
0.351 |
|
| 2017 |
Ho TH, Kapur P, Eckel-Passow JE, Christie A, Joseph RW, Serie DJ, Cheville JC, Thompson RH, Homayoun F, Panwar V, Brugarolas J, Parker AS. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017733238. PMID 28976794 DOI: 10.1200/Jco.2017.73.3238 |
0.39 |
|
| 2017 |
Zhang Y, Udayakumar D, Cai L, Hu Z, Kapur P, Kho EY, Pavía-Jiménez A, Fulkerson M, de Leon AD, Yuan Q, Dimitrov IE, Yokoo T, Ye J, Mitsche MA, Kim H, ... ... Brugarolas J, et al. Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI. Jci Insight. 2. PMID 28768909 DOI: 10.1172/Jci.Insight.94278 |
0.413 |
|
| 2017 |
Wolff NC, Vega-Rubin-de-Celis S, Xie XJ, Castrillon DH, Kabbani W, Brugarolas J. Correction for Wolff et al., "Cell-Type-Dependent Regulation of mTORC1 by REDD1 and the Tumor Suppressors TSC1/TSC2 and LKB1 in Response to Hypoxia". Molecular and Cellular Biology. 37. PMID 28620021 DOI: 10.1128/Mcb.00224-17 |
0.303 |
|
| 2017 |
Gu YF, Cohn S, Christie A, McKenzie T, Wolff NC, Do QN, Madhuranthakam A, Pedrosa I, Wang T, Dey A, Busslinger M, Xie XJ, Hammer RE, McKay RM, Kapur P, ... Brugarolas J, et al. Modeling Renal Cell Carcinoma in mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade. Cancer Discovery. PMID 28473526 DOI: 10.1158/2159-8290.Cd-17-0292 |
0.447 |
|
| 2017 |
Eckel-Passow JE, Serie DJ, Cheville JC, Ho TH, Kapur P, Brugarolas J, Thompson RH, Leibovich BC, Kwon ED, Joseph RW, Parker AS. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. Bmc Urology. 17: 19. PMID 28327121 DOI: 10.1186/s12894-017-0209-3 |
0.323 |
|
| 2017 |
Bowman IA, Pedrosa I, Kapur P, Brugarolas J. Renal Cell Carcinoma With Pulmonary Metastasis and Metachronous Non-Small Cell Lung Cancer. Clinical Genitourinary Cancer. PMID 28258962 DOI: 10.1016/J.Clgc.2017.01.026 |
0.37 |
|
| 2017 |
De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, Rini BI, et al. Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. PMID 28254206 DOI: 10.1016/J.Clgc.2017.01.005 |
0.379 |
|
| 2017 |
Stukalin I, Wells C, Fraccon AP, Pasini F, Porta C, Moreira RB, Srinivas S, Bowman IA, Brugarolas J, Lee J, Donskov F, Beuselinck B, Bamias A, Rini BI, Sim H, et al. Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Journal of Clinical Oncology. 35: 498-498. DOI: 10.1200/Jco.2017.35.6_Suppl.498 |
0.326 |
|
| 2017 |
Pedrosa I, Zhang Y, Udayakumar D, Cai L, Hu Z, Kapur P, Diaz de Leon A, Yuan Q, Yokoo T, Ye J, Mitsche M, Kim H, McDonald J, Xi Y, Madhuranthakam AJ, ... ... Brugarolas J, et al. Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative magnetic resonance imaging. Journal of Clinical Oncology. 35: 460-460. DOI: 10.1200/Jco.2017.35.6_Suppl.460 |
0.392 |
|
| 2017 |
Le TC, Brugarolas J. The enrollment status of patients with brain metastases in metastatic renal cell carcinoma: A query of clinicaltrials.gov. Journal of Clinical Oncology. 35: e16070-e16070. DOI: 10.1200/Jco.2017.35.15_Suppl.E16070 |
0.329 |
|
| 2017 |
Wang CJ, Christi A, Bowman IA, Xie XJ, Laine AM, Desai NB, Timmerman RD, Brugarolas J, Hannan R. Stereotactic Ablative Radiotherapy Prolongs Surveillance and Delays Initiation of Systemic Therapy in Patients with Renal Cancer Metastases International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.1255 |
0.373 |
|
| 2016 |
Ishihara D, Louder K, Akter M, Ahn C, Margulis V, Arriaga Y, Courtney K, Timmerman RD, Brugarolas J, Hannan R. Phase 2 Trial of High-Dose Interleukin-2 (IL-2) and Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)-Interim Analysis of i-SAbR IL-2 Trial. International Journal of Radiation Oncology, Biology, Physics. 96: S96-S97. PMID 27676061 DOI: 10.1016/J.Ijrobp.2016.06.241 |
0.337 |
|
| 2016 |
Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, ... ... Brugarolas J, et al. Targeting Renal Cell Carcinoma with a HIF-2 antagonist. Nature. PMID 27595394 DOI: 10.1038/Nature19796 |
0.383 |
|
| 2016 |
Tran TA, Leong HS, Pavia-Jimenez A, Fedyshyn S, Yang J, Kucejova B, Sivanand S, Spence P, Xie XJ, Peña-Llopis S, Power N, Brugarolas J. FGFR-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant RCC. Molecular and Cellular Biology. PMID 27141054 DOI: 10.1128/Mcb.00189-16 |
0.381 |
|
| 2016 |
Fay AP, Velasco Gd, Gray KP, Ho TH, Song J, Kapur P, Albiges L, McDermott DF, Heng DYC, Brugarolas J, Choueiri TK, Signoretti S. The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT). Journal of Clinical Oncology. 34: 616-616. DOI: 10.1200/Jco.2016.34.2_Suppl.616 |
0.373 |
|
| 2016 |
Wang CJ, Cai X, Kim DW, Huelsmann L, Meyer JJ, Pedrosa I, Brugarolas J, Margulis V, Timmerman RD, Hannan R. The effect of stereotactic ablative radiotherapy on time to change of systemic therapy in extra-cranial renal cell carcinoma metastases. Journal of Clinical Oncology. 34: 533-533. DOI: 10.1200/Jco.2016.34.2_Suppl.533 |
0.379 |
|
| 2016 |
Bowman IA, Le T, Christie A, Brugarolas J. Incidence of brain metastases in metastatic renal cell carcinoma in the era of targeted therapies. Journal of Clinical Oncology. 34: e16103-e16103. DOI: 10.1200/Jco.2016.34.15_Suppl.E16103 |
0.412 |
|
| 2016 |
Wells JC, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Knox JJ, Beuselinck B, Rha SY, Agarwal N, Brugarolas J, Lee J, Pal SK, Srinivas S, Ernst DS, Vaishampayan UN, et al. Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC). Journal of Clinical Oncology. 34: 4554-4554. DOI: 10.1200/Jco.2016.34.15_Suppl.4554 |
0.436 |
|
| 2016 |
Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Wang K, Wallace E, Josey JA, Choueiri TK. A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma. Journal of Clinical Oncology. 34: 2506-2506. DOI: 10.1200/Jco.2016.34.15_Suppl.2506 |
0.361 |
|
| 2016 |
Eckel-Passow JE, Serie DJ, Cheville JC, Ho TH, Harrington SM, Hilton T, Lohse C, Shreders A, Kapur P, Brugarolas J, Thompson RH, Leibovich BC, Kwon ED, Joseph RW, Parker AS. Abstract 10: Concordance of BAP1, PBRM1, Ki-67, and TOPOIIa protein expression in primary clear cell renal cell carcinoma tumors and patient-matched metastatic tumors Clinical Cancer Research. 22: 10-10. DOI: 10.1158/1557-3265.Pmsclingen15-10 |
0.394 |
|
| 2016 |
Pavia-Jimenez A, Chen W, Hill H, Christie A, Yousuf Q, Williams N, Xie X, Kapur P, Brugarolas J. Abstract IA10: Renal cancer tumorgrafts: A validated model to evaluate novel targeted therapies Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-Ia10 |
0.432 |
|
| 2015 |
Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Tong P, Wang J, Castle EP, Stanton ML, Cheville JC, Jonasch E, Brugarolas J, Parker AS. Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 26516698 DOI: 10.1038/modpathol.2015.123 |
0.354 |
|
| 2015 |
Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, Frenkel E, Parker AS, Brugarolas J. Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression. The Journal of Urology. PMID 26300218 DOI: 10.1016/J.Juro.2015.07.113 |
0.366 |
|
| 2015 |
Wolff NC, Pavía-Jiménez A, Tcheuyap VT, Alexander S, Vishwanath M, Christie A, Xie XJ, Williams NS, Kapur P, Posner B, McKay RM, Brugarolas J. High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma. Oncotarget. 6: 16951-62. PMID 26219258 |
0.316 |
|
| 2015 |
Staub D, Hannan R, Thomas K, Jiang S, Pedrosa I, Kapur P, Brugarolas J, Wang J. TU-AB-BRA-02: Predicting Gene Mutations in Renal Cell Carcinoma Using Machine Learning. Medical Physics. 42: 3586. PMID 26128803 DOI: 10.1118/1.4925507 |
0.346 |
|
| 2015 |
Denard B, Pavia-Jimenez A, Chen W, Williams NS, Naina H, Collins R, Brugarolas J, Ye J. Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome. Plos One. 10: e0129233. PMID 26110425 DOI: 10.1371/Journal.Pone.0129233 |
0.42 |
|
| 2015 |
Gayed BA, Gillen J, Christie A, Peña-Llopis S, Xie XJ, Yan J, Karam JA, Raj G, Sagalowsky AI, Lotan Y, Margulis V, Brugarolas J. Prospective Evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with Renal Cell Carcinoma. Bmc Urology. 15: 24. PMID 25885592 DOI: 10.1186/S12894-015-0019-4 |
0.41 |
|
| 2015 |
Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Parasramka M, Cheville JC, Wu KJ, Frenkel E, Rakheja D, Stefanius K, Brugarolas J, Parker AS. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. Urologic Oncology. 33: 23.e9-14. PMID 25465300 DOI: 10.1016/J.Urolonc.2014.10.014 |
0.37 |
|
| 2015 |
Durinck S, Stawiski EW, PavÃa-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, ... ... Brugarolas J, et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nature Genetics. 47: 13-21. PMID 25401301 DOI: 10.1038/Ng.3146 |
0.33 |
|
| 2015 |
Shreders A, Joseph RW, Serie D, Kapur P, Ho TH, Eckel-Passow J, Brugarolas J, Parker AS. High concordance of BAP1 and PBRM1 expression in patient-matched primary and metastatic ccRCC tumors. Journal of Clinical Oncology. 33: 507-507. DOI: 10.1200/Jco.2015.33.7_Suppl.507 |
0.386 |
|
| 2015 |
Swaika A, Ho TH, Kapur P, Serie D, Eckel-Passow J, Brugarolas J, Parker AS, Joseph RW. Clinical impact of loss of H3K36me3 expression in patients with clear cell renal cell carcinoma. Journal of Clinical Oncology. 33: 4563-4563. DOI: 10.1200/Jco.2015.33.15_Suppl.4563 |
0.442 |
|
| 2015 |
Williams K, Mazzola C, Brugarolas J, Power N, Chambers A, Leong H. Abstract 5099: Abrogation of cancer cell extravasation in renal cell carcinoma PDX lines via invadopodia dysregulation mediated by PAK1 inhibitors Cancer Research. 75: 5099-5099. DOI: 10.1158/1538-7445.Am2015-5099 |
0.419 |
|
| 2015 |
Wang CJ, Huelsmann L, Hannan R, Timmerman RD, Meyer JJ, Abdulrahman RE, Nedzi LA, Margulis V, Brugarolas J, Kim DWN. Extracranial Renal Cell Carcinoma Treated With Stereotactic Ablative Body Radiation Therapy Leads to Excellent Lesional Control International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.1069 |
0.38 |
|
| 2014 |
Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1968-76. PMID 24821879 DOI: 10.1200/JCO.2012.45.2003 |
0.317 |
|
| 2014 |
Wolff NC, McKay RM, Brugarolas J. REDD1/DDIT4-independent mTORC1 inhibition and apoptosis by glucocorticoids in thymocytes. Molecular Cancer Research : McR. 12: 867-77. PMID 24615339 DOI: 10.1158/1541-7786.Mcr-13-0625 |
0.324 |
|
| 2014 |
Kapur P, Christie A, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, Shariat SF, Bensalah K, Rioux-Leclercq N, Xie XJ, Lotan Y, Margulis V, Brugarolas J. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. The Journal of Urology. 191: 603-10. PMID 24076305 DOI: 10.1016/j.juro.2013.09.041 |
0.348 |
|
| 2014 |
Joseph RW, Kapur P, Serie D, Eckel-Passow J, Ho TH, Brugarolas J, Parker AS. Loss of BAP1 and PBRM1 protein expression and its association with clear cell renal cell carcinoma-specific survival. Journal of Clinical Oncology. 32: 414-414. DOI: 10.1200/Jco.2014.32.4_Suppl.414 |
0.43 |
|
| 2014 |
Joseph RW, Kapur P, Serie D, Cheville JC, Eckel-Passow J, Parasramka M, Ho TH, Kwon ED, Thompson RH, Brugarolas J, Parker AS. Association of loss of BAP1 expression in cell renal cell carcinomas with PDL1 expression. Journal of Clinical Oncology. 32: 4530-4530. DOI: 10.1200/Jco.2014.32.15_Suppl.4530 |
0.44 |
|
| 2014 |
Ho TH, Kapur P, Joseph RW, Serie D, Eckel-Passow J, Parasramka M, Cheville JC, Brugarolas J, Parker AS. Loss of BAP1 and PBRM1 expression in non-clear cell renal cell carcinomas compared to clear cell renal cell carcinomas. Journal of Clinical Oncology. 32: 4529-4529. DOI: 10.1200/Jco.2014.32.15_Suppl.4529 |
0.465 |
|
| 2014 |
Mazzola C, Willie C, Pardhan S, MacMillan C, Siddiqui K, Billia M, Izawa J, Chin J, Chambers A, Brugarolas J, Power N, Leong H. 187 Predicting targeted therapy tumor resistance in renal cell carcinoma patient-derived xenografts implanted into chicken embryos European Urology Supplements. 13: e187-e187a. DOI: 10.1016/S1569-9056(14)60185-8 |
0.301 |
|
| 2014 |
Mazzola CR, Willie C, MacMillan C, Siddiqui KM, Billia M, Izawa JI, Chambers AF, Brugarolas J, Tram A, Power N, Leong HS. Mp35-15 Developing A Patient-Derived Xenograft Model Using Chicken Embryos To Predict Targeted Therapy Tumor Resistance In Renal Cell Carcinomas The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1058 |
0.441 |
|
| 2014 |
Kim D, Bhuiyan M, Toffesi-Tcheuyup V, Pavia-Jimenez A, Holloman E, Huelsmann L, Gao D, Hannan R, Chen B, Saha D, Brugarolas J. Validated Tumor Graft Model Reveals Delayed Local Recurrence of Renal Cell Tumors After High-Dose Single Fraction Ablative Radiation Therapy International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.2314 |
0.381 |
|
| 2014 |
Joseph RW, Kapur P, Serie DJ, Eckel-Passow JE, Parasramka M, Ho T, Cheville JC, Frenkel EP, Rakheja D, Brugarolas J, Parker A. Erratum: Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma (Cancer DOI: 10.1002/cncr.28521) Cancer. 120: 1752-1753. DOI: 10.1002/Cncr.28615 |
0.421 |
|
| 2013 |
Kapur P, Peña-Llopis S, Christie A, Zhrebker L, PavÃa-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. The Lancet. Oncology. 14: 159-67. PMID 23333114 DOI: 10.1016/S1470-2045(12)70584-3 |
0.433 |
|
| 2013 |
Jacobs C, Kim DW, Straka C, Timmerman RD, Brugarolas J. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: e114-7. PMID 23319695 DOI: 10.1200/Jco.2012.46.0501 |
0.405 |
|
| 2013 |
Sudarshan S, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, Margulis V, Patard JJ, Escudier B, Linehan WM. Metabolism of kidney cancer: from the lab to clinical practice. European Urology. 63: 244-51. PMID 23063455 DOI: 10.1016/J.Eururo.2012.09.054 |
0.308 |
|
| 2012 |
Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, Kinch L, Hambuch T, Jain S, Lotan Y, Margulis V, ... ... Brugarolas J, et al. BAP1 loss defines a new class of renal cell carcinoma. Nature Genetics. 44: 751-9. PMID 22683710 DOI: 10.1038/Ng.2323 |
0.355 |
|
| 2012 |
Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, et al. State of the science: an update on renal cell carcinoma. Molecular Cancer Research : McR. 10: 859-80. PMID 22638109 DOI: 10.1158/1541-7786.Mcr-12-0117 |
0.424 |
|
| 2012 |
Sonpavde G, Amiel G, Margulis V, Link RE, Lerner SP, Raj G, Mayer WA, Palapattu GS, Lotan Y, Sagalowsky AI, Higgins LC, Tello SA, Pavia-Jimenez A, VonMerveldt D, Brugarolas J. Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps4678 |
0.371 |
|
| 2012 |
Ali H, Yan J, Arriaga YE, Xie X, Brugarolas J. Brain metastases (BMs) from metastatic renal cell carcinoma (RCC) in patients (pts) treated with molecularly targeted agents (MTAs). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E15066 |
0.345 |
|
| 2012 |
Peña-Llopis S, Vega-Rubín-De-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, Kinch L, Hambuch T, Jain S, Lotan Y, Margulis V, ... ... Brugarolas J, et al. Erratum: BAP1 loss defines a new class of renal cell carcinoma (Nature Genetics (2012) 44 (751-759)) Nature Genetics. 44: 1072-1072. DOI: 10.1038/Ng0912-1072B |
0.343 |
|
| 2011 |
Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp SH, Abel EJ, Brugarolas J, Raj G, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapy on the level of renal cell carcinoma (RCC) venous tumor thrombus. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e15002. PMID 28020546 DOI: 10.1200/Jco.2011.29.15_Suppl.E15002 |
0.417 |
|
| 2011 |
Peña-Llopis S, Brugarolas J. TFEB, a novel mTORC1 effector implicated in lysosome biogenesis, endocytosis and autophagy. Cell Cycle (Georgetown, Tex.). 10: 3987-8. PMID 22101272 DOI: 10.4161/Cc.10.23.18251 |
0.339 |
|
| 2011 |
Kinch L, Grishin NV, Brugarolas J. Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell. 20: 418-20. PMID 22014567 DOI: 10.1016/J.Ccr.2011.10.005 |
0.33 |
|
| 2011 |
Peña-Llopis S, Vega-Rubin-de-Celis S, Schwartz JC, Wolff NC, Tran TA, Zou L, Xie XJ, Corey DR, Brugarolas J. Regulation of TFEB and V-ATPases by mTORC1. The Embo Journal. 30: 3242-58. PMID 21804531 DOI: 10.1038/Emboj.2011.257 |
0.306 |
|
| 2011 |
Kucejova B, Peña-Llopis S, Yamasaki T, Sivanand S, Tran TA, Alexander S, Wolff NC, Lotan Y, Xie XJ, Kabbani W, Kapur P, Brugarolas J. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Molecular Cancer Research : McR. 9: 1255-65. PMID 21798997 DOI: 10.1158/1541-7786.MCR-11-0302 |
0.359 |
|
| 2011 |
Wolff NC, Vega-Rubin-de-Celis S, Xie XJ, Castrillon DH, Kabbani W, Brugarolas J. Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia. Molecular and Cellular Biology. 31: 1870-84. PMID 21383064 DOI: 10.1128/Mcb.01393-10 |
0.319 |
|
| 2011 |
Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. European Urology. 59: 912-8. PMID 21367518 DOI: 10.1016/J.Eururo.2011.02.032 |
0.415 |
|
| 2011 |
Yamasaki T, Tran TA, Oz OK, Raj GV, Schwarz RE, Deberardinis RJ, Zhang X, Brugarolas J. Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC. Nature Reviews. Urology. 8: 165-71. PMID 21304509 DOI: 10.1038/Nrurol.2010.234 |
0.365 |
|
| 2011 |
Cost N, Delacroix S, Sleeper J, Smith P, Youssef R, Chapin B, Karam J, Culp S, Abel EJ, Brugarolas J, Raj G, Sagalowsky A, Wood C, Margulis V. 1771 The Impact Of Targeted Molecular Therapies On The Level Of Renal Cell Carcinoma Vena Caval Tumor Thrombus The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2099 |
0.441 |
|
| 2009 |
Zhou J, Brugarolas J, Parada LF. Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. Human Molecular Genetics. 18: 4428-41. PMID 19692352 DOI: 10.1093/Hmg/Ddp398 |
0.41 |
|
| 2008 |
Brugarolas J, Lotan Y, Watumull L, Kabbani W. Sirolimus in metatastic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3457-60. PMID 18612163 DOI: 10.1200/JCO.2008.16.4590 |
0.314 |
|
| 2007 |
Brugarolas J. Renal-cell carcinoma--molecular pathways and therapies. The New England Journal of Medicine. 356: 185-7. PMID 17215538 DOI: 10.1056/NEJMe068263 |
0.316 |
|
| 2004 |
Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes & Development. 18: 2893-904. PMID 15545625 DOI: 10.1101/Gad.1256804 |
0.338 |
|
| 2004 |
Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine. 10: 594-601. PMID 15156201 DOI: 10.1038/Nm1052 |
0.307 |
|
| 1999 |
Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proceedings of the National Academy of Sciences of the United States of America. 96: 1002-7. PMID 9927683 DOI: 10.1073/Pnas.96.3.1002 |
0.615 |
|
| 1998 |
Xu Y, Yang EM, Brugarolas J, Jacks T, Baltimore D. Involvement of p53 and p21 in cellular defects and tumorigenesis in Atm-/- mice. Molecular and Cellular Biology. 18: 4385-90. PMID 9632822 DOI: 10.1128/Mcb.18.7.4385 |
0.599 |
|
| 1998 |
Brugarolas J, Bronson RT, Jacks T. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells Journal of Cell Biology. 141: 503-514. PMID 9548727 DOI: 10.1083/Jcb.141.2.503 |
0.616 |
|
| 1998 |
Attardi L, Brugarolas J, Heinrichs A. HDAC, a key to pRb tumour suppression? Trends in Cell Biology. 8: 182. DOI: 10.1016/S0962-8924(98)01277-X |
0.493 |
|
| 1997 |
Montes de Oca Luna R, Amelse LL, Chavez-Reyes A, Evans SC, Brugarolas J, Jacks T, Lozano G. Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nature Genetics. 16: 336-7. PMID 9241268 DOI: 10.1038/Ng0897-336 |
0.588 |
|
| 1997 |
Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. Nature Medicine. 3: 721-2. PMID 9212093 DOI: 10.1038/Nm0797-721 |
0.547 |
|
| 1996 |
Attardi LD, Lowe SW, Brugarolas J, Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. The Embo Journal. 15: 3693-3701. DOI: 10.1002/J.1460-2075.1996.Tb00739.X |
0.708 |
|
| 1995 |
Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377: 552-7. PMID 7566157 DOI: 10.1038/377552A0 |
0.602 |
|
| Show low-probability matches. |